Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge
- PMID: 8229111
- DOI: 10.1016/0895-4356(93)90102-7
Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge
Abstract
Standards are lacking for validation of drug causality assessment methods. An original model is proposed using a positive rechallenge as an external standard. This model was used to validate the novel causality assessment method (RUCAM) described in the previous article (Part I; J Clin Epidemiol 1993; 46: 1323). Seventy seven reports of drug-induced acute liver injuries with positive rechallenge were collected from the medical literature and divided into 49 cases and 28 controls. The RUCAM was applied to information obtained prior to readministration. The score was significantly higher (p < 10(-4)) in cases than in controls with high levels of sensitivity, specificity and predictive values. It is concluded that (1) adverse drug reaction reports with a positive rechallenge can provide a standard for validation of causality assessment methods, (2) RUCAM applied to drug-induced liver injuries has been validated.
Similar articles
-
Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.J Clin Epidemiol. 1993 Nov;46(11):1323-30. doi: 10.1016/0895-4356(93)90101-6. J Clin Epidemiol. 1993. PMID: 8229110
-
Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM.Drug Saf. 2017 Aug;40(8):715-727. doi: 10.1007/s40264-017-0541-2. Drug Saf. 2017. PMID: 28508325
-
Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran.Int J Clin Pharmacol Ther. 2008 Jul;46(7):327-39. doi: 10.5414/cpp46327. Int J Clin Pharmacol Ther. 2008. PMID: 18793587
-
Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch?Drug Saf. 2018 Aug;41(8):735-743. doi: 10.1007/s40264-018-0654-2. Drug Saf. 2018. PMID: 29502198 Review.
-
Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method.Expert Opin Drug Metab Toxicol. 2018 Nov;14(11):1169-1187. doi: 10.1080/17425255.2018.1539077. Epub 2018 Oct 29. Expert Opin Drug Metab Toxicol. 2018. PMID: 30354694 Review.
Cited by
-
Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series.Dig Dis Sci. 2016 Sep;61(9):2741-8. doi: 10.1007/s10620-016-4181-7. Epub 2016 May 3. Dig Dis Sci. 2016. PMID: 27142670 Free PMC article.
-
Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM).Diagnostics (Basel). 2021 Mar 6;11(3):458. doi: 10.3390/diagnostics11030458. Diagnostics (Basel). 2021. PMID: 33800917 Free PMC article. Review.
-
Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease.Drug Saf. 2016 Aug;39(8):729-44. doi: 10.1007/s40264-016-0423-z. Drug Saf. 2016. PMID: 27091053 Review.
-
Acute liver failure due to amoxicillin and amoxicillin/clavulanate.Dig Dis Sci. 2005 Oct;50(10):1785-90. doi: 10.1007/s10620-005-2938-5. Dig Dis Sci. 2005. PMID: 16187174 Review.
-
Diagnostic Biomarkers in Liver Injury by Drugs, Herbs, and Alcohol: Tricky Dilemma after EMA Correctly and Officially Retracted Letter of Support.Int J Mol Sci. 2019 Dec 27;21(1):212. doi: 10.3390/ijms21010212. Int J Mol Sci. 2019. PMID: 31892250 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical